<DOC>
	<DOCNO>NCT00127569</DOCNO>
	<brief_summary>This trial aim study efficacy 4 weekly cycle rituximab HIV-infected patient multicentric Castleman disease ( giant lymph node hyperplasia ) dependent chemotherapy . Efficacy assess complete response rate day 60 . The patient follow day 365 .</brief_summary>
	<brief_title>Rituximab Treatment HIV Associated Multicentric Castleman Disease Dependent Chemotherapy</brief_title>
	<detailed_description>HIV-related multicentric Castleman disease ( MCD ) lymphoproliferative disorder characterize lymphadenopathy angiofollicular hyperplasia plasma cell infiltration , associate KSHV/HHV-8 . Patients typically systemic manifestation fever associate lymphadenopathy , hepatosplenomegaly , respiratory symptom , peripheral edema , cytopenia , hypergammaglobulinemia , hypoalbuminemia , high level serum C reactive protein ( CRP ) . Symptoms correlate important increase KSHV/HHV-8 DNA peripheral blood mononuclear cell . HIV-MCD characterize rapidly progressive often fatal course . HIV-MCD often refractory treatment . Vinca alkaloid produce frequent short-lived response , patient remain dependant upon chemotherapy . Lymph node patient HIV-MCD specifically harbor virus B cell locate mantle zone , stain positively CD20 surface antigen . Rituximab , humanize monoclonal anti-CD20 antibody , report effective case , conflict data case . The optimal schedule infusion remain unclear . Kaposi 's sarcoma often associate HIV-MCD , development aggressive non-Hodgkin 's lymphoma rare outcome .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Giant Lymph Node Hyperplasia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Confirmed multicentric Castleman disease , dependence vinblastine VP16 least 3 month , whenever splenectomized At least one Castleman crisis since onset chemotherapy Ongoing highly active antiretroviral therapy ( HAART ) least 3 month No threshold CD4 cell count HIVRNA Signed write informed consent Prior treatment rituximab Evolutive lymphoma Kaposi 's sarcoma needing treatment Absence effective contraception Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Giant Lymph Node Hyperplasia</keyword>
	<keyword>Herpesvirus 8 , Human</keyword>
	<keyword>Rituximab ( Mabthera )</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>